<DOC>
	<DOCNO>NCT00207714</DOCNO>
	<brief_summary>Multicenter , randomize , double-blind , placebo-controlled , 5-arm , dose-ranging study ass efficacy subcutaneous injection Golimumab ( CNTO 148 ) , 50 100 mg , either 2- 4- week interval subject active RA despite MTX therapy .</brief_summary>
	<brief_title>An Efficacy Safety Study CNTO 148 Subcutaneous Injection Compared With Placebo Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description>This experimental medical research study . The purpose study determine Golimumab safe effective treatment rheumatoid arthritis . Subjects receive subcutaneous injection either 50 100 mg Golimumab placebo every two four week infusion infliximab week 20 , 22 , 28 , 36 , 44 48 week</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Diagnosis RA accord American College Rheumatology criterion least 3 month prior screen Have active Rheumatoid Arthritis time screen baseline , define 6 swollen joint 6 tender joint additional laboratory criterion Have inflammatory disease , include limited ankylosing spondylitis , systemic lupus erythematosus , Lyme disease Received diseasemodifying antirheumatic drug ( [ DMARDs ] eg , D penicillamine , hydroxychloroquine , chloroquine , oral parenteral gold , interleukin [ IL ] 1 receptor antagonist [ anakinra ] , azathioprine , sulphasalazine , agent MTX ) within 4 week prior first study dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>CNTO 148</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Joint pain</keyword>
	<keyword>Arthritis</keyword>
</DOC>